Back to search
FDAFDA · Food and drugs·Recall number Z-2887-2026

HardyDisk AST Cefiderocol 30®g (FDC30) REF Z9435 HardyDisk AST Cefiderocol 30®g (FDC30) for in vitro agar diffusion susceptibility testing is indicated when there is the need to determine the susceptibility of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii complex and Stenotrophomonas maltophilia to Cefiderocol,

Published August 12, 2026 · Recall initiated: June 8, 2026

Summary

FDA records medical device Class II recall Z-2887-2026, published August 12, 2026 and initiated June 8, 2026. Recalling firm: Hardy Diagnostics; Status: Ongoing; Reported quantity: 43 units; Lot: Catalog Number: Z9435 UD-DI code: Pending Lot Number: 543461. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Due to incorrect cartridges include in affected products that there is the potential for false-susceptible or false-resistant susceptibility results and may lead to selection of an ineffective antimicrobial therapy, potentially resulting in delayed appropriate treatment, prolonged infection, or worsening clinical outcome.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Hardy Diagnostics
Distributor
U.S. Nationwide distribution in the states of AZ, CA, FL, ID, IN, MA, MS, NJ, NV, NY, OH, PA, and TN.
Lot
Catalog Number: Z9435 UD-DI code: Pending Lot Number: 543461
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was HardyDisk AST Cefiderocol 30®g (FDC30) REF Z9435 HardyDisk AST Cefiderocol 30®g (FDC30) for in vitro agar diffusion susceptibility testing is indicated when there is the need to determine the susceptibility of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii complex and Stenotrophomonas maltophilia to Cefiderocol, recalled?

Yes. FDA published recall Z-2887-2026 on August 12, 2026. Reported hazard: Due to incorrect cartridges include in affected products that there is the potential for false-susceptible or false-resistant susceptibility results and may lead to selection of an ineffective antimicrobial therapy, potentially resulting in delayed appropriate treatment, prolonged infection, or worsening clinical outcome.

What should I do if I have this product?

Voluntary: Firm initiated · Letter